Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 118 clinical trials
featured
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

  • 182 views
  • 25 Mar, 2021
  • 1 location
Study of VIR-2218 + VIR-3434 in Subjects With Chronic Hepatitis B Virus Infection

This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218+ VIR-3434 and will be assessed for safety, tolerability, and efficacy

  • 0 views
  • 01 Aug, 2021
  • 25 locations
A Study of JNJ-73763989 JNJ-56136379 Nucleos(t)Ide Analogs and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 + nucleos[t]ide analog [NA] and pegylated interferon alpha-2a [PegIFN-alpha2a].

  • 0 views
  • 08 Sep, 2021
  • 12 locations
The Clinical Cure Project of Chronic Hepatitis B in China

Chronic hepatitis B is a global public health problem, with nearly 700,000 deaths each year because of hepatitis B-related diseases. Recent studies have found that some patients who have used

hepatitis b surface
cirrhosis
chronic hepatitis
cancer
hepatitis b antigen
  • 6 views
  • 24 Jan, 2021
  • 1 location
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels. This study is part of HepB Wings Platform Trial (PLATFORMPAHPB2001).

  • 6 views
  • 01 Mar, 2020
  • 32 locations
  • 0 views
  • 22 Jan, 2021
  • 1 location
A Study to Evaluate the Reactogenicity Safety Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.

A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed subjects under nucleo(s)tide treatment.

hepatitis b surface
cirrhosis
vaccination
chronic hepatitis
hepatitis b core antibody
  • 17 views
  • 05 Jun, 2021
  • 34 locations
A Study of JNJ-73763989 Pegylated Interferon Alpha-2a Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA) with or without JNJ-56136379.

  • 0 views
  • 10 Sep, 2021
  • 58 locations
Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection

Influence of antiviral treatment to the long term prognosis of patients with chronic HBV infection. The aim of antiviral treatment for HBV is to reduce the long term severe complications. In this study, the investigators divided patients with chronic HBV infection into two groups, which start early antiviral treatment and …

lamivudine
hepatitis b antigen
antiviral drugs
telbivudine
antiviral treatment
  • 11 views
  • 07 Nov, 2020
  • 2 locations
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection

This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection

  • 0 views
  • 08 Aug, 2021
  • 28 locations